Drug Profile
HCP 1101
Alternative Names: HCP-1101Latest Information Update: 10 Oct 2015
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Small molecules
- Mechanism of Action Reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 10 Oct 2015 Discontinued - Phase-III for Benign prostatic hyperplasia in South Korea (unspecified route)
- 19 Mar 2015 Phase-III clinical trials in Benign prostatic hyperplasia in South Korea (unspecified route)